<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Anti-Asthmatics:</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\7.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Anti-Asthmatics: <a name='6:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<br>

<p>
<img src="./Pharmacology/pasted_image.png">+
</p>

<p>
⇒  inflammatory disease of the airways:
</p>

<p>
<ul>
<li>Acute bronchoconstriction → shrotness of breath,cough,chest tighness,weheezing,rapid respiration<b>a</b></li>
<li>not a progressive disease but is chronic and if undertreated may incur airway remodeling → ↑ severity of exacerbation </li>
</ul>
</p>

<p>
<b>A.Goals of Therapy:</b><br>
→ reduction in impairment &amp; reduction of risk 
</p>

<p>
1.Reducing impairment: <br>
→ ↓ intensity &amp; frequency of asthma symptoms.<br>
<ul>
<li>use of shrot acting medication</li>
<li>maintain normal pulmonary function → activity levels</li>
</ul>
</p>

<p>
2.Reducing risk<br>
→ ↓ adverse outcome of asthma and it's treatment<br>
<ul>
<li>prevent exacerbation and minimize need of emergency</li>
<li>prevent loss of lung function / child growth</li>
<li>minimal or non adverse effects.</li>
</ul>
</p>

<p>
<b>B.Role of inflammation in asthma.</b><br>
→ ↑ secretion of mucus and inflammation  of bronchial wall+contranction of bronchial smooth muscle → bronchoconstriction → airflow obstruction
</p>

<br>

<h3>Adregernic agonist:</h3>

<p>
 → β-2-activity<br>
→ drugs of choice in <b>mild </b>asthma<br>
→ occasional,intermittent symptoms<br>
→ potent bronchodilators → relax airway smooth muscle
</p>

<p>
<b>1.quick relief</b><br>
<ul>
<li>rapid onest of action (5-30min)</li>
<li>provide relief for 4-6hrs</li>
<li>no anti-inflammatory effects</li>
</ul>
</p>

<h4>⇒ Albuterol</h4>

<p>
<ul>
<li>maximal attanable bronchodilation</li>
<li>skeletal-muscle tremors</li>
</ul>
</p>

<p>
<b>2.Long-term </b>
</p>

<h4>⇒ Salmeterol &amp; Formoterol</h4>

<p>
<ul>
<li>long-acting β2-agonist</li>
<li>chemical analogue to albuterol  → having a lipophilic side chain(↑ affinity )</li>
<li>providing bronchodilation for at least 12hrs</li>
<li><b>CI:</b> use of LABA alone (should  be used with asthma controller medicaiton)</li>
<li>corticosteroids drug of choise for long-term therapy</li>
</ul>
</p>

<h3>Corticosteroids</h3>

<p>
→ ICS (inhaled corticosteroids)<br>
<ul>
<li>first choice in patients with any degree of presistent asthma.(mild/moderate/severe → (may require addition of short-acting glucorticosteroids)</li>
</ul>
</p>

<p>
<b>1.action in lugs</b>
</p>

<p>
→ do not directly affect the airway smooth muscle<br>
→ directly targets underlying airway inflammation → ↓ inflammatory cascade(eosinophilis,macrophages,T lymphocytes) → reversing mucosal edema → ↓ permability of capillaries &amp; inhibiting the release of leukotriens.<br>
→ after long term use of ICS → ↓ hyperrsponsiviness of the ariway smooth muscle to a variety of bronchoconstriction stimuli
</p>

<p>
<b>2.route of admin.</b><br>
<b>α.inhalation</b><br>
→inhalation technique is critical<br>
⇒ MDIs have propellants that eject the active medication from the canister<br>
<ul>
<li>slowly &amp; deeply inhale just before and throughout activation</li>
</ul>
<div style='padding-left: 30pt'>
(to avoid impaction of the med into laryngeal mucosa rather than bronchial smooth muscsle)
</div>
<ul>
<li>improper use can lead to mouth/pharynx deposition of the drug</li>
</ul>
</p>

<p>
ICS → DPIS which require different  inhalter technique<br>
<ul>
<li>quicky &amp; deeply inhlation</li>
<li>AE: oropharyngeal candidiasis due to local supression</li>
</ul>
</p>

<p>
<b>b.Oral/Systemic</b><br>
→ severe exacebration of asthma (status asthmaticus) may require IV admin of <i>methyprednisolone or PO prednisone.</i><br>
<ul>
<li>after improvement of patient doses ↓ </li>
</ul>
</p>

<p>
<b>c.Spacers</b><br>
→ large volume chambers attached to MDI<br>
<ul>
<li>↓ desposition of the drug in the mouth </li>
</ul>
<div style='padding-left: 30pt'>
   (↓ the velocity of the aerosol before entering the mouth → alowing larger particles to be deposited in the device)<br>
→ smaller higher-velocity-particles reach the target airway tissue)
</div>
<ul>
<li>↓ adrenal supression (reduce the amount of glucocorticoid in oropharynx)</li>
<li>adviced for ↓ 5yrs &amp; eldery patients</li>
</ul>
</p>

<p>
<b>3.AE</b><br>
→ oral/parental glucocorticoids have a variety of potentially serious adverse effects <b>(Q24-Corticosteroids)</b><br>
→ ICS(spacer) have a few system effects
</p>

<h1>III.  ALTERNATIVE DRUGS USED TO TREAT ASTHMA</h1>

<p>
→ moderate/severe allergic asthma<br>
→ in conjuction with ICS → NO SOLO
</p>

<h2>A.Leukotriene antagonist:</h2>

<p>
⇒ LEUKOTRIENE LTB4 &amp; cysteinyl leukotriens,LTC4,LTD4,LTE4 are products of 5-lipooxygenase pathway of arachanoid acid metabolism<br>
<ul>
<li>lipooxygenase found in mast cells,basophilis,eosinophilis,neutrophilis</li>
</ul>
→ LTB4 → potent chemoattractant for neutrophilis and eosinophilis
</p>

<p>
→ LTC/LTD/LTE4 → constric bronchiolar smooth muscle,↑ endothelial permability and promote mucus secretion
</p>

<h3>Zileuton/Zafirlukast/Montelukast</h3>

<p>
⇒ <i>Zileuton → </i>selective/specific inhibitor of both leukotrienes<br>
⇒ <i>Zafirlukast and Montelukast → </i>selective revesible inhibitors of the cysteinyl leukotriene-1 receptor<br>
<ul>
<li>Montelukast is the market leader → dosing recommendation for children 6 months and older </li>
</ul>
<div style='padding-left: 450pt'>
→ chewable tablets/granule
</div>
 formulation<br>
<div style='padding-left: 450pt'>
→ prevention of exercise-induced bronchospams
</div>
→ ALL 3 drugs : prophylaxis of asthma<br>
<div style='padding-left: 180pt'>
   modest reudction of β-blockers/corticosteroids<br>
   improve respiratory function
</div>
</p>

<p>
<b>1.Pharmacokinetics</b>
</p>

<p>
→ Orally active<br>
<ul>
<li>food impair Zafirlukast absorption</li>
<li>90% of each drug is bound to plasma protein</li>
<li>extensively metabolized</li>
<li>Zileuton excreted in urine</li>
<li>Zafirlukast/Montelukast undergo billary excrection</li>
</ul>
</p>

<p>
<b>2.AE</b>
</p>

<p>
→ ↑ in serum hepatic enzymes (when enzyme exceed 3to5 times the upper limit of normal → discontinuation)<br>
→ headache,dyspepsia<br>
→ Zafirlukast/Zileuton inhibit P450(↑ serum level of warfarin)
</p>

<h2>B.Cromolyn</h2>

<br>

<p>
→ effective prophylactic and anti-inflammataory agent<br>
→ is not useful to manage actue asthma attack (is not direct bronchodilator)<br>
→ block initiation of immediate/delayed asthma reactions → allergen → induced-excercise bronchoconstriction
</p>

<p>
→ available in nebulized solutions<br>
→ 4-6 week trial → recom for pregnant/children<br>
→ poorly absorbed,minor AE,short acting(requires frequent daily dosing)<br>
→ should not replace ICS/β2<br>
→ inhibit mast cell degranulation and release of histamine
</p>

<h2>C.Cholinergic antagonist</h2>

<br>

<p>
→ are less effective than b-2-adrenergic agonist<br>
→ block cagally mediated contraction of airway smooth muscle
</p>

<p>
<i>Inhaled Ipratropium  (derivative of atropine)</i><br>
<ul>
<li>is useful in patients who are unable to tolerate adrenergic agonist</li>
<li>slow onest and nearly free of side effects</li>
</ul>
</p>

<h2>D.Theophylline</h2>

<br>

<p>
→ bronchodilator → relieves airway obstruction in chronic asthma<br>
→well absorbed by GIT<br>
→ narrow therapeutic window,high side effect profile,dd interaction<br>
→ seizures,potential fatal arrhythmias <br>
→ metabolized in the liver <br>
→ CYPA12 and 3A4 substrate →  many DD interactions
</p>

<h2>E.Omalizumab</h2>

<p>
→ moderate/severe allergic asthma (for patients which poorly controled by the conventional therapy)<br>
→ recombinant DNA-derived monoclonal antibody <br>
→ selectively bind to immunoglobulin receptor on the surface of mast/basophilis cells → limits the degree of release of mediators of the allergic response<br>
→ not currently used as first line therapy agent(high cost,limitation on dosage,limited clinical trial data)
</p>

<br>

<p>
<img src="./Pharmacology/pasted_image001.png"><br>
<img src="./Pharmacology/pasted_image003.png">
</p>

<br>
<br>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>43.6kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>179kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>54.7kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>37.5kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
